Telesis Bio, Inc.

Equities

TBIO

US1920031010

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.44 USD -2.22% Intraday chart for Telesis Bio, Inc. -5.52% +10.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Earnings Flash (TBIO) TELESIS BIO Reports Q4 Revenue $7M MT
Telesis Bio, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (TBIO) TELESIS BIO Posts Q3 Revenue $5.6M, vs. Street Est of $7.4M MT
Telesis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Telesis Bio, Inc. Provides Earnings Guidance for 2023 CI
Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement CI
Telesis Bio, Inc. Announces Board Changes CI
Telesis Bio Names William Kullback as CFO MT
Telesis Bio Inc. Appoints William J. Kullback Chief Financial Officer CI
North American Morning Briefing : Stock Futures -2- DJ
Telesis Bio Downgraded by KeyBanc Over 'Tepid' Biopharma Spending, 'Significant Dilution' MT
KeyBanc Downgrades Telesis Bio to Sector Weight From Overweight, Cites 'Limited Top-Line Visibility' Amid 'Tepid Biopharma Spending Environment' MT
Transcript : Telesis Bio, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (TBIO) TELESIS BIO Posts Q2 Revenue $8.7M, vs. Street Est of $8.6M MT
Telesis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Top Premarket Gainers MT
Telesis Bio, Inc. Appoints Paul Meister as Director CI
Telesis Bio, Inc. announced that it has received $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor CI
Telesis Bio Secures $28 Million Preferred Equity Financing MT
Telesis Bio, Inc. announced that it expects to receive $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor CI
Telesis Bio Makes First Commercial Shipment of BioXp Select DNA Cloning Kit; Shares Rise MT
Telesis Bio Makes First Commercial Shipment of BioXp NGS Library Prep Kit MT
Wall Street Set to Open Higher; Import Prices Rebound More Than Expected MT
Telesis Bio Q1 Loss Narrows While Sales Increase MT
Translate Bio Shares Plunge 24% After Hours; Q1 Revenue Misses Expectations But Net Loss Narrows in Line With Consensus MT
Chart Telesis Bio, Inc.
More charts
Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of virtually error-free DNA and mRNA at a useable scale. Its on-market and planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp DBC, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, BioXp DBC kits, Benchtop reagents and Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS). BioXp 3250 system is a push-button, walkaway, end-to-end automated workstation that offers endpoint-ready synthetic DNA in as few as 8 hours and mRNA in less than 24 hours. BioXp DBC is engaged in delivering on-demand enzymatic DNA synthesis with design-to-endpoint-ready synthetic RNA in as few as 24 hours.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.44
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Telesis Bio, Inc. - Nasdaq
  4. News Telesis Bio, Inc.
  5. Codex DNA : Taps CleanCap mRNA Capping Technology From Maravai LifeSciences Unit TriLink